Viral neuraminidase inhibitors show limited efficacy in mice infected with H7N9 influenza A viruses isolated from humans. Although baloxavir marboxil protected mice from lethal challenge infection with a low pathogenic avian influenza H7N9 virus isolated from a human, its efficacy in mice infected with a recent highly pathogenic version of H7N9 human isolates is unknown. Here, we examined the efficacy of baloxavir marboxil in mice infected with a highly pathogenic human H7N9 virus, A/Guangdong/17SF003/2016. Treatment of infected mice with a single 1.5 mg/kg dose of baloxavir marboxil protected mice from the highly pathogenic human H7N9 virus infection as effectively as oseltamivir treatment at 50 mg/kg twice a day for five days. Daily treatment for five days at 15 or 50 mg/kg of baloxavir marboxil showed superior therapeutic efficacy, largely preventing virus replication in respiratory organs. These results indicate that baloxavir marboxil is a valuable candidate treatment for human patients suffering from highly pathogenic H7N9 virus infection.
Introduction
Treatment of zoonotic influenza with neuraminidase (NA) inhibitors that target the viral sialidase activity of NA is thought to be effective. However, the efficacy of these inhibitors against H7N9 viruses is limited in mice [1, 2] . In 2018, a novel antiviral, baloxavir marboxil, which targets the viral endonuclease activity of PA, was approved in several countries for the treatment of seasonal influenza. Baloxavir marboxil is also considered to be an antiviral drug against emerging zoonotic influenza viruses. In patients infected with a seasonal influenza virus, baloxavir treatment reduced the viral load after only 1 day of treatment, which is more rapid than treatment with an NA inhibitor; however, the time to symptom improvement was similar between baloxavir marboxil and NA inhibitor treatments [3] . After baloxavir marboxil treatment, mutant viruses harboring the PA-I38T/M/F mutation with reduced susceptibility to baloxavir marboxil were occasionally reported in patients [3] [4] [5] . The resistant virus has also caused influenza in humans [6, 7] .
Human H7N9 virus infections were first reported in March 2013 [8] and the virus was shown to possess amino acid mutations important for mammalian adaptation and to have the potential to transmit between ferrets via respiratory droplets [1, [9] [10] [11] . During the fifth epidemic wave in the 2016-2017 influenza season, highly pathogenic H7N9 virus that retained the mammalian-adaptive mutations and the ability to transmit between ferrets was detected in both humans and chickens [2, [12] [13] [14] . As of June 2 of 6 2019, a total of 1568 laboratory-confirmed human cases, including 615 deaths, have been reported [15] . Due to a nationwide domestic poultry vaccination campaign that began in September 2017 in China, human cases drastically decreased from mid-2017 [16] . However, the H7N9 viruses have not been eradicated because several outbreaks in poultry and a human infection by the highly pathogenic H7N9 virus were reported after the vaccination campaign [17] .
Materials, Methods, and Results
To evaluate the efficacy of baloxavir marboxil in vivo infection with the H7N9 virus, baloxavir marboxil was orally administered to mice at 5 and 50 mg/kg twice a day for five days and was shown to have completely protected them from lethal challenge infection with a low pathogenic avian H7N9 human isolate, A/Anhui/1/2013 [18] . Highly pathogenic A/Guangdong/17SF003/2016 virus, which possesses enhanced polymerase activity in mammals due to PB2-482R, PB2-588V, and PA-497R [12] is more pathogenic than A/Anhui/1/2013 because it causes a systemic infection in mice, ferrets, and macaques [2] ; this greater pathogenicity may affect the efficacy of baloxavir marboxil. Although A/Guangdong/17SF003/2016 showed reduced growth in human bronchial epithelial cells [2] , this virus possesses the A100V, R262K, V387I, N394D, I465V, and K497R mutations in PA that may affect sensitivity to baloxavir marboxil compared with A/Anhui/1/2013. Accordingly, here, we assessed the efficacy of baloxavir marboxil against this highly pathogenic human H7N9 virus in vitro and in vivo.
To examine the efficacy of baloxavir marboxil in vitro, virus growth was tested in the absence or presence of baloxavir acid. Madin-Darby canine kidney (MDCK) cells were infected with A/Guangdong/17SF003/2016 (H7N9) virus at a multiplicity of infection (MOI) of 0.001 and incubated for 24 or 48 h with Eagle's minimal essential medium (EMEM) supplemented with 0.3% BSA, 1 µg/mL trypsin, and 0, 40, or 160 nM baloxavir acid. Virus titers were measured by means of plaque assays with MDCK cells. A/Guangdong/17SF003/2016 grew efficiently in MDCK cells in the absence of baloxavir marboxil, reaching a virus titer of approximately 7.8 log 10 PFU/mL at 24 and 48 h post infection ( Figure 1 ). In contrast, in the presence of 40 and 160 nM baloxavir acid, A/Guangdong/17SF003/2016 replication was completely suppressed at both timepoints ( Figure 1 ). These results indicate that baloxavir marboxil is effective against the highly pathogenic H7N9 virus in vitro.
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Discussion
Here, we evaluated the in vivo therapeutic efficacy of baloxavir marboxil against a highly pathogenic human H7N9 virus. Baloxavir marboxil given as a single dose or as a 5-day treatment course improved the survival of mice infected with the highly pathogenic human H7N9 virus and suppressed its replication in the respiratory organs. Baloxavir marboxil also protected mice from a low pathogenic avian H7N9 human isolate, A/Anhui/1/2013 [18] . Since treatment with NA inhibitors have little antiviral effects against the low pathogenic and highly pathogenic human H7N9 viruses in mice [1, 2] , baloxavir marboxil would likely be the first choice to treat patients suffering from a H7N9 virus infection in the clinical setting.
Treating with antivirals always encounters the potential problem of emergence of resistant mutants. Viruses resistant to baloxavir marboxil frequently emerged in patients within 3-5 days of treatment [3] [4] [5] with the PA-I38T/M/F mutation known to increase the IC 50 value by 10-to 50-fold [4, 5] .
In our experiments, viruses resistant to baloxavir marboxil or oseltamivir phosphate were not detected. However, to reduce the risk of emergence of resistant viruses, it is essential to minimize virus replication in the respiratory organs after treatment. To achieve this, treatment with high-dose baloxavir marboxil for several days would be a reasonable approach based on our data. This proposed treatment regimen is different from current baloxavir treatment for seasonal influenza; however, based on the relatively high frequency of viruses with reduced baloxavir sensitivity, even for seasonal influenza, a combination therapy of baloxavir marboxil and other antivirals for seasonal influenza may be considered as another therapeutic option to avoid the emergence of viruses with reduced baloxavir sensitivity.
In summary, baloxavir marboxil showed high therapeutic efficacy against a highly pathogenic human H7N9 virus. Since the risk of reemergence of H7N9 viruses persists, stockpiling baloxavir marboxil should be considered for pandemic preparation.
